{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05025605",
            "orgStudyIdInfo": {
                "id": "BXCL501-105"
            },
            "organization": {
                "fullName": "BioXcel Therapeutics Inc",
                "class": "INDUSTRY"
            },
            "briefTitle": "Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder",
            "officialTitle": "A Randomized, Double-blind, Placebo-controlled Study to Determine Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder",
            "therapeuticArea": [
                "Mental Health",
                "Other"
            ],
            "study": "determining-efficacy-and-safety-of-in-agitation-associated-with-pediatric-schizophrenia-and-bipolar-disorder"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-08",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-08-27",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-07-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-07-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-08-24",
            "studyFirstSubmitQcDate": "2021-08-24",
            "studyFirstPostDateStruct": {
                "date": "2021-08-27",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-08-09",
            "lastUpdatePostDateStruct": {
                "date": "2023-08-14",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "BioXcel Therapeutics Inc",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "Cognitive Research Corporation",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a study of the efficacy and safety of BXCL501 in children and adolescents with acute agitation and either bipolar disorder or schizophrenia.",
            "detailedDescription": "The study will enroll approximately 140 subjects randomized to dose regimens of 80 \u00b5g or 120 \u00b5g BCXL501 or placebo (Group one), or 60 \u00b5g BCXL501 or placebo (Group two; Europe only). Subjects with acute agitation will include male and female children and adolescents who are either newly admitted to a hospital setting or already admitted and experiencing acute agitation. Subjects will be domiciled in a clinical research setting or hospitalized to remain under medical supervision while undergoing screening procedures to assess eligibility. Efficacy and safety assessments will be conducted periodically before and after dosing."
        },
        "conditionsModule": {
            "conditions": [
                "Schizophrenia",
                "Schizo-Affective Disorder",
                "Schizophreniform; Schizophrenic",
                "Bipolar Disorder I",
                "Bipolar Disorder II"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "Study will randomize subjects in Group one 1:1:1 to receive BXCL501 80 \u03bcg, BXCL501 120 \u03bcg, or matching placebo film; Group two 2:1 to receive BXCL501 60 \u03bcg or matching placebo film",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "maskingDescription": "Double-Blind, Placebo-controlled",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 140,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "80 Micrograms",
                    "type": "EXPERIMENTAL",
                    "description": "Sublingual film containing 80 micrograms Dexmedetomidine",
                    "interventionNames": [
                        "Drug: BXCL501 80 Micrograms"
                    ]
                },
                {
                    "label": "120 Micrograms",
                    "type": "EXPERIMENTAL",
                    "description": "Sublingual film containing 120 micrograms Dexmedetomidine",
                    "interventionNames": [
                        "Drug: BXCL501 120 Micrograms"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Sublingual Placebo film",
                    "interventionNames": [
                        "Drug: Placebo Film"
                    ]
                },
                {
                    "label": "60 Micrograms",
                    "type": "EXPERIMENTAL",
                    "description": "Sublingual film containing 60 micrograms Dexmedetomidine Europe Only",
                    "interventionNames": [
                        "Drug: BXCL501 60 Micrograms"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "BXCL501 80 Micrograms",
                    "description": "Sublingual film containing 80 Micrograms BXCL501",
                    "armGroupLabels": [
                        "80 Micrograms"
                    ],
                    "otherNames": [
                        "Dexmedetomidine"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo Film",
                    "description": "Matching Sublingual Placebo film",
                    "armGroupLabels": [
                        "Placebo"
                    ],
                    "otherNames": [
                        "Placebo"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "BXCL501 120 Micrograms",
                    "description": "Sublingual film containing 120 Micrograms BXCL501",
                    "armGroupLabels": [
                        "120 Micrograms"
                    ],
                    "otherNames": [
                        "Dexmedetomidine"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "BXCL501 60 Micrograms",
                    "description": "Sublingual film containing 60 Micrograms BXCL501 Europe Only",
                    "armGroupLabels": [
                        "60 Micrograms"
                    ],
                    "otherNames": [
                        "Dexmedetomidine"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Absolute change from baseline in the Positive and Negative Syndrome Scale - Excited Component (PEC) total score",
                    "description": "The Positive and Negative Syndrome Scale - Excited Component (PEC) comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (minimum) to 7 (maximum). The PEC, the sum of these 5 subscales, thus ranges from 5 (absence of agitation) to 35 (extremely severe)",
                    "timeFrame": "120 minutes - Group one only"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Absolute change from baseline in the Positive and Negative Syndrome Scale - Excited Component (PEC) total score",
                    "description": "The Positive and Negative Syndrome Scale - Excited Component (PEC) comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (minimum) to 7 (maximum). The PEC, the sum of these 5 subscales, thus ranges from 5 (absence of agitation) to 35 (extremely severe)",
                    "timeFrame": "90, 60, 45, 30, 20,10 minutes - Group one only"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Male and female subjects between the ages of 10-17 years, inclusive, with bipolar disorder (DSM-5 criteria) and 13-17 years, inclusive, in subjects with schizophrenia (DSM-5 criteria).\n2. Patients who are judged to be clinically agitated at Screening and Baseline with a total score of \u226514 on the 5 items comprising the PANSS Excited Component (PEC).\n3. Patients who have a score of \u2265 4 on at least 1 of the 5 items on the PEC at Baseline.\n4. Participants who agree to use a medically acceptable and effective birth control method\n\nExclusion Criteria:\n\n1. Patients with agitation caused by acute intoxication, including alcohol or drugs of abuse (with the exception of THC) during urine screening.\n2. Use of benzodiazepines or other hypnotics or oral or short-acting intramuscular antipsychotic drugs in the 4 hours before study treatment.\n3. Patients who are judged to be at significant risk of suicide.\n4. Patients with serious or unstable medical illnesses.\n5. Patients who have received an investigational drug within 30 days prior to the current agitation episode.\n6. Patients who are considered by the investigator, for any reason, to be an unsuitable candidate for receiving the study drug.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "10 Years",
            "maximumAge": "17 Years",
            "stdAges": [
                "CHILD"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Regan Dickinson",
                    "role": "CONTACT",
                    "phone": "475-228-2920",
                    "email": "rdickinson@bioxceltherapeutics.com"
                },
                {
                    "name": "Carl Gommoll",
                    "role": "CONTACT",
                    "phone": "475-355-5177",
                    "email": "cgommoll@bioxceltherapeutics.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Robert Risinger, MD",
                    "affiliation": "BioXcel Therapeutics",
                    "role": "STUDY_CHAIR"
                }
            ],
            "locations": [
                {
                    "facility": "BioXcel Clinical Research Site",
                    "status": "RECRUITING",
                    "city": "Anaheim",
                    "state": "California",
                    "zip": "92805",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "BioXcel CTM",
                            "role": "CONTACT",
                            "phone": "475-254-5899",
                            "email": "info@bioxceltherapeutics.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.83529,
                        "lon": -117.9145
                    }
                },
                {
                    "facility": "Bioxcel Clinical Research Site",
                    "status": "RECRUITING",
                    "city": "Hialeah",
                    "state": "Florida",
                    "zip": "33016",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Bioxcel CTM",
                            "role": "CONTACT",
                            "phone": "475-254-5899",
                            "email": "info@bioxceltherapeutics.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.8576,
                        "lon": -80.27811
                    }
                },
                {
                    "facility": "BioXcel Clinical Research Site",
                    "status": "RECRUITING",
                    "city": "Atlanta",
                    "state": "Georgia",
                    "zip": "30331",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Bioxcel CTM",
                            "role": "CONTACT",
                            "phone": "475-254-5899",
                            "email": "info@bioxceltherapeutics.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.749,
                        "lon": -84.38798
                    }
                },
                {
                    "facility": "Bioxcel Clinical Research Site",
                    "status": "RECRUITING",
                    "city": "Decatur",
                    "state": "Georgia",
                    "zip": "30030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Bioxcel CTM",
                            "role": "CONTACT",
                            "phone": "475-254-5899",
                            "email": "info@bioxceltherapeutics.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.77483,
                        "lon": -84.29631
                    }
                },
                {
                    "facility": "BioXcel Clinical Research Site",
                    "status": "RECRUITING",
                    "city": "DeSoto",
                    "state": "Texas",
                    "zip": "75115",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Bioxcel CTM",
                            "role": "CONTACT",
                            "phone": "475-254-5899",
                            "email": "info@bioxceltherapeutics.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.58986,
                        "lon": -96.85695
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000012559",
                    "term": "Schizophrenia"
                },
                {
                    "id": "D000001714",
                    "term": "Bipolar Disorder"
                },
                {
                    "id": "D000019964",
                    "term": "Mood Disorders"
                },
                {
                    "id": "D000011618",
                    "term": "Psychotic Disorders"
                }
            ],
            "ancestors": [
                {
                    "id": "D000019967",
                    "term": "Schizophrenia Spectrum and Other Psychotic Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                },
                {
                    "id": "D000068105",
                    "term": "Bipolar and Related Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M15376",
                    "name": "Schizophrenia",
                    "asFound": "Schizophrenia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4996",
                    "name": "Bipolar Disorder",
                    "asFound": "Bipolar Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21835",
                    "name": "Mood Disorders",
                    "asFound": "Affective Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14452",
                    "name": "Psychomotor Agitation",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "asFound": "Schizo Affective Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21838",
                    "name": "Schizophrenia Spectrum and Other Psychotic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M226",
                    "name": "Bipolar and Related Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000020927",
                    "term": "Dexmedetomidine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000006993",
                    "term": "Hypnotics and Sedatives"
                },
                {
                    "id": "D000002492",
                    "term": "Central Nervous System Depressants"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018712",
                    "term": "Analgesics, Non-Narcotic"
                },
                {
                    "id": "D000000700",
                    "term": "Analgesics"
                },
                {
                    "id": "D000018689",
                    "term": "Sensory System Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                },
                {
                    "id": "D000058647",
                    "term": "Adrenergic alpha-2 Receptor Agonists"
                },
                {
                    "id": "D000000316",
                    "term": "Adrenergic alpha-Agonists"
                },
                {
                    "id": "D000000322",
                    "term": "Adrenergic Agonists"
                },
                {
                    "id": "D000018663",
                    "term": "Adrenergic Agents"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M22662",
                    "name": "Dexmedetomidine",
                    "asFound": "Twice daily",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10043",
                    "name": "Hypnotics and Sedatives",
                    "relevance": "LOW"
                },
                {
                    "id": "M4032",
                    "name": "Analgesics",
                    "relevance": "LOW"
                },
                {
                    "id": "M20786",
                    "name": "Analgesics, Non-Narcotic",
                    "relevance": "LOW"
                },
                {
                    "id": "M20746",
                    "name": "Adrenergic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M3668",
                    "name": "Adrenergic alpha-Agonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M3673",
                    "name": "Adrenergic Agonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}